Ce Shi, Yang Li, Xing Zou, Dayong Yao, Jia Wei, Zhiyu Liu, Yue Su, Boqian Yu, Xin Zhang, Zhenkun Wang, Hui Liang, Hao Gang, Yanhong Zhao, Mengmeng Gu
{"title":"AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia.","authors":"Ce Shi, Yang Li, Xing Zou, Dayong Yao, Jia Wei, Zhiyu Liu, Yue Su, Boqian Yu, Xin Zhang, Zhenkun Wang, Hui Liang, Hao Gang, Yanhong Zhao, Mengmeng Gu","doi":"10.1080/10428194.2025.2504161","DOIUrl":null,"url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a heterogeneous clonal disease of hematopoietic progenitor cells and the most common malignant myeloid disease in adults. Although significant progress has been made in treatment, the outlook remains bleak, and new therapeutic targets need to be sought. AP-2 complex subunit mu (AP2M1) is a core component of the clathrin-mediated endocytic machinery, AP2M1 plays a critical role in cancer progression. However, its function in acute myeloid leukemia (AML) progression remains unclear. Our study reveals that AP2M1 is highly expressed in AML and is associated with poor prognosis. Mechanistic studies suggest that this effect may result through cell cycle arrest and is associated with the tumor microenvironment, and our findings suggest that AP2M1 is a potential oncogene and prognostic marker for AML.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-15"},"PeriodicalIF":2.2000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2504161","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Acute myeloid leukemia (AML) is a heterogeneous clonal disease of hematopoietic progenitor cells and the most common malignant myeloid disease in adults. Although significant progress has been made in treatment, the outlook remains bleak, and new therapeutic targets need to be sought. AP-2 complex subunit mu (AP2M1) is a core component of the clathrin-mediated endocytic machinery, AP2M1 plays a critical role in cancer progression. However, its function in acute myeloid leukemia (AML) progression remains unclear. Our study reveals that AP2M1 is highly expressed in AML and is associated with poor prognosis. Mechanistic studies suggest that this effect may result through cell cycle arrest and is associated with the tumor microenvironment, and our findings suggest that AP2M1 is a potential oncogene and prognostic marker for AML.
期刊介绍：
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
